HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tyers, G. F. O. Search for Related Content PubMed PubMed Citation Articles by Tyers, G. F. O.

Ann Thorac Surg 1989;48:390-396
© 1989 The Society of Thoracic Surgeons

---

Articles

FDA Recalls: How Do Pacemaker Manufacturers Compare?

Division of Cardiovascular and Thoracic Surgery, The University of British Columbia, and Division of Cardiovascular Surgery, The Vancouver General Hospital, Vancouver, British Columbia, Canada

Accepted for publication June 7, 1989.

^* Address reprint requests to Dr Tyers, C314; 700 W 10th Ave, Vancouver, BC V5Z 1L9, Canada

To evaluate an apparent perception that there is no difference in reliability among the products of the major cardiac pacing system manufacturers, an extensive review of US Food and Drug Administration regulatory actions was performed. The study period was July 1974 through June 1987. The total number of affected devices was collected for each manufacturer. Available sales data were used to calculate their percentage of recalled products during two time periods. The percentage of potentially high-risk devices (Food and Drug Administration class I and II recalls) was high for one company, moderate for one, and relatively low for the rest. Potential biases in some other sources of reliability information, as well as implications for regulatory policies, are discussed. The data reported establish that there have been past deficiencies in recall management. Although further pacing device recalls are probable, appropriate early regulatory and manufacturer action should help to assure that both the immense cost and patient distress caused by pacer and related product problems in the past can be minimized in the future.

This article has been cited by other articles:

				A. Auricchio, M. Gropp, S. Ludgate, P. Vardas, J. Brugada, S. G. Priori, and Writing Committee for the European Heart Rhythm As European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance. Europace, January 1, 2006; 8(5): 313 - 322. [Full Text] [PDF]

				W. H. Maisel, M. O. Sweeney, W. G. Stevenson, K. E. Ellison, and L. M. Epstein Recalls and Safety Alerts Involving Pacemakers and Implantable Cardioverter-Defibrillator Generators JAMA, August 15, 2001; 286(7): 793 - 799. [Abstract] [Full Text] [PDF]